Details of the Drug

General Information of Drug (ID: DMZGX27)

• Drug Name: Mesdopetam
• Synonyms: mesdopetam; IRL790; IRL-790; HD4QV8GX26; 1403894-72-3; UNII-HD4QV8GX26; N-[2-(3-fluoro-5-methylsulfonylphenoxy)ethyl]propan-1-amine; 1-Propanamine, N-(2-(3-fluoro-5-(methylsulfonyl)phenoxy)ethyl)-; MESDOPETAM [INN]; MESDOPETAM [WHO-DD]; CHEMBL4594447; SCHEMBL13732678; GTPL10811; OSBPYFBXSLJHCR-UHFFFAOYSA-N; AKOS040756735; HY-109150; CS-0115974; N-[2-(3-FLUORO-5-METHYLSULFONYL-PHENOXY)ETHYL]PROPAN-1-AMINE; N-{2-[3-FLUORO-5-(METHYLSULFONYL)PHENOXY]ETHYL}-N-PROPYLAMINE

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Phase 2	[1]

• Drug Type: Small molecule
• Chemical Identifiers:
  Formula: C12H18FNO3S
  Canonical SMILES: CCCNCCOC1=CC(=CC(=C1)S(=O)(=O)C)F
  InChI: InChI=1S/C12H18FNO3S/c1-3-4-14-5-6-17-11-7-10(13)8-12(9-11)18(2,15)16/h7-9,14H,3-6H2,1-2H3
  InChIKey: OSBPYFBXSLJHCR-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 70980485
  UNII: HD4QV8GX26
  DrugBank ID: DB16229
  TTD ID: DQNF41
• Drug ADMET Endpoint Profile (DAE)NEW: Click to Jump to the Detailed DAE Information of This Drug

References

• [1] ClinicalTrials.gov (NCT04435431) A Randomized, Double-blind, Placebo-controlled Phase IIB Study Evaluating the Efficacy of Mesdopetam on Daily ON-time Without Troublesome Dyskinesia in Patients With Parkinson's Disease. U.S.National Institutes of Health.